Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PODCAST: Masimo CEO Bets Smart Glasses Are The Future Of Patient Monitoring

Executive Summary

When Masimo chairman and CEO Joe Kiani saw Atheer's smart glasses and virtual reality platform, he thought the possibilities for patient monitoring were endless. Now the two companies have joined forces and are moving quickly to turn virtual reality into a clinical reality with a prototype interactive display and novel patient monitoring system that they say has the power to transform health care and the market for patient monitoring, which is estimated at more than $2 billion in the US alone according to an upcoming report from Medtech Insight.

You may also be interested in...



US Patient Monitoring Devices Market Forecast To Grow $500 Million By 2019 Despite Pricing Pressures, Spending Slowdown

Despite slowdowns in capital equipment spending and strong pricing pressures, the US patient monitoring device market will grow by over $500 million between 2014 and 2019, reaching more than $2.5 billion by 2019 – a CAGR of almost 5%. Several factors are driving growth in this market, including the need for seamless solutions that can provide monitoring from hospital to home, and the growing adoption of portable and wearable technologies.

Masimo Root Monitoring System Gains FDA Clearance

Masimo has gained FDA clearance for its Root Patient Monitoring Platform, a noninvasive, continuous monitoring platform with interoperability and technologies that have demonstrated improved patient safety and cost of care.

Big Pharma CEOs Suggest Policy Changes As They Return To Beijing

Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel